ARRY-520: Interim Phase I/II data

Interim data from 13 patients in the Phase I/II 520-212 trial showed that 1.25 mg/m 2 IV ARRY-520 monotherapy on days 1 and 2 of a 14-day cycle was the MTD after a dose-limiting toxicity of grade 4 ne...